Open access
718
Views
0
CrossRef citations to date
0
Altmetric
Real-World Evidence and Medical Affairs
Clinical profiles and outcomes in patients with inflammatory bowel disease receiving standard and escalated doses of targeted therapies: findings from a global real-world study
Axel Dignassa Department of Medicine I, Agaplesion Markus Hospital, Goethe University, Frankfurt/Main, Germany
, Isabel Redondob Eli Lilly and Company, Lisbon, Portugal
, Petra Streitc Eli Lilly and Company, Vernier, Switzerland
, Susanne Hartzd Eli Lilly and Company, Bracknell, UK
, Gamze Gursese Eli Lilly and Company, Istanbul, Turkey
, Hannah Knightf Adelphi Real World, Bollington, UK
, Sophie Barlowf Adelphi Real World, Bollington, UK
, Niamh Harveyf Adelphi Real World, Bollington, UKhttps://orcid.org/0000-0002-2855-297X
& Theresa Hunterg Eli Lilly and Company, Indianapolis, Indiana, USACorrespondence[email protected]
https://orcid.org/0000-0001-8412-9175
show allhttps://orcid.org/0000-0001-8412-9175
Pages 1695-1705
|
Received 10 Jul 2023, Accepted 30 Oct 2023, Published online: 14 Nov 2023
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.